

Strategies for Managing the Tsunami of Medical Information:

AI and Beyond



David R. Penberthy, MD MBA

Associate Professor and Program Director

University of Virginia Department of Radiation Oncology

President, ACCC 2022-2023

February 17, 2024



Disclosures

Name	Employment	Funding Sources	Ownership & investments	Leadership
David R. Penberthy, MD, MBA	UVa Health AstraZeneca Startups and Real Estate	None	CHS stock Mutual funds Startup - ROMTech Startup - OncoAI	ACCC Board of Trustees

I would like to acknowledge

K. Singh Sahni, MD
Alfred M. Strash, PhD
Faye Flemming RN, BSN, OCN
Tracey Tatum, RN, NP
Cliff Robinson, MD
Peter Diamandis, MD
Matt Devino, MPH
Mark Liu, MPH
Amy Ellis, RN
Douglas Flora, MD
Sarah McGough, PhD
John Frownfelter, MD, FACP
Rick Baehner, MD
Blythe Adamson, PhD, MPH
Kevin Davies, PhD
Michael Dake, MD
Ryan Langdale

for their assistance with this presentation



ASSOCIATION OF COMMUNITY CANCER CENTERS

LEADING EDUCATION AND ADVOCACY ORGANIZATION FOR THE
CANCER CARE COMMUNITY

- ~50 years old (founded 1974)
- Powerful network of ~40,000 multidisciplinary practitioners from over 2100 hospitals and practices nationwide in every state
- ~2/3 of the nation's cancer patients are treated by a member of ACCC

www.accc-cancer.org

Learning objectives


Statement of the
cancer problem

Current state of
multidisciplinary
care

AI and Future
directions



Magnitude



Estimated number of new cases from 2020 to 2040, Both sexes, age [0-85+]

All cancers

Africa + Latin America and Caribbean + Northern America + Europe + Oceania + Asia

2020





2040



Cancer Incidence Worldwide

Breakdown of the estimated 12.7 million new cases, World-age standardised incidence rates and the most commonly diagnosed cancers by the different regions of the world, 2008.


International Agency for Research on Cancer



Source: GLOBOCAN 2008, v. 1.2, Cancer Incidence and Mortality Worldwide. IARC, 2010 (<http://globocan.iarc.fr>) Map updated February 2011

<http://info.cancerresearchuk.org/cancerstats/>

GDP issues




Gross domestic product


\$27.36 trillion

2023


**National spending on
healthcare goods and
services**



**Healthcare expenditures
as a percent of GDP**



So how are we doing?



5

Takeaways from the Cancer Facts & Figures Report 2022



Lung cancer patients are being diagnosed earlier, and living longer.



In 2022, there will be an estimated 1,918,030 new cancer diagnoses, and 609,360 cancer deaths.





Cancer mortality is declining at an accelerating rate.



The racial, socioeconomic, and geographic disparities for preventable cancers are alarming.




The rate of advanced-stage prostate cancer diagnosis increased by 4%-6% each year from 2014 -2018.





Source: [Statistics and Graphs | Division of Cancer Control and Population Sciences \(DCCPS\)](#) accessed 2/1/24

Growth of Physicians and Administrators in U.S.



Bureau of Labor Statistics; NCHS; Himmelstein/Woolhandler analysis of CPS
Managers shown as moving average of current year and two previous years

US Debt and Taxes




National debt \$34T and counting
www.usdebtclock.org

US CANCER INCIDENCE AND MORTALITY

Incidence rates, 2008-2012
By state, all cancer types combined
Per 100,000, age adjusted to the 2000 US standard population

392.9 - 418.4 418.41 - 443.9 443.91 - 469.4 469.41 - 494.9 494.90 - 520.4




Data Source: North American Association of Central Cancer Registries (NAACCR), 2015
© 2016 American Cancer Society

Cancer

Death rates, 2008-2012
By state, all cancer types combined
Per 100,000, age adjusted to the 2000 US standard population

127.6 - 142.96 142.97 - 158.32 158.33 - 173.68 173.69 - 189.04 189.04 - 204.4



Data Source: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention, 2015

© 2016 American Cancer Society

CancerStatisticsCenter.org



THE MEDICAL LITERATURE CHALLENGE

Pubmed

Daily: ~4,000 Weekly: ~28,000 Monthly: ~120,000

Annually: ~1.44 million articles

10% oncology related

Daily - ~400 Weekly - ~2800 Monthly - ~12,000

Annually- ~144,000

These figures only represent a fraction of the medical information being generated, as they do not account for other sources like clinical trials, patents, guidelines, conference proceedings, and more. Additionally, the growth of data in fields like genomics and digital health is further accelerating the expansion of medical information.



GROWTH OF GUIDELINES



Changes in Length and Complexity of Clinical Practice Guidelines in Oncology, 1996-2019

Benjamin H. Kann, MD; Skyler B. Johnson, MD; Hugo J. W. L. Aerts, PhD; Raymond H. Mak, MD; Paul L. Nguyen, MD

Figure 1. Page Volume of National Comprehensive Cancer Network Clinical Practice Guidelines by Disease Site, 1996-2019






Figure 2. References Cited in National Comprehensive Cancer Network Clinical Practice Guidelines by Disease Site, 1996-2019



“Further approaches, including guideline stratification by evidence level and the use of artificial intelligence for decision support, should be investigated as ways to synthesize data and improve cancer decision-making.”



Google HEALTH



“It is often easier
(and faster) to make
something 10x better
than it would be to
make it 10% better.”

— Astro Teller





Business And Society

AI Won't Replace Humans — But Humans With AI Will Replace Humans Without AI

August 04, 2023

The New
World of Work
Karim R. Lakhani,
Harvard Business
School Professor

Harvard
Business
Review



WHAT IS THIS?


- Bell Labs scientists John Bardeen, Walter Brattain, and William Shockley invented the transistor in 1947, and won the 1956 Nobel Prize in Physics
- John McCarthy coined the term “artificial intelligence” in 1956



The History of AI




Parmida Beigi, PhD
@bigdataqueen



The robots are coming.

Ray Kurzweil c. 2006



arXiv


<https://arxiv.org> Cornell University

Free distribution service and open access for **>2.3M** articles in physics, mathematics, computer science, quantitative biology, quantitative finance, statistics, electrical engineering and systems science, and economics

~1200 daily submissions

a place of connection, linking together people and ideas, and connecting them with the world of open science

(also bioRxiv,



THE EVOLUTION OF ARTIFICIAL INTELLIGENCE



Artificial Intelligence (AI) – the development of computer systems that are able to perform tasks that typically require human intelligence, such as recognizing patterns, making decisions, and solving problems



- AI has the potential to revolutionize the healthcare industry by enabling us to diagnose diseases and develop personalized treatments faster and more accurately than ever before.

DEEP BLUE – HOW AI BEAT THE WORLD CHAMPION



ALPHAGO BEAT LEE SEDOL




a**MACHINE AND DEEP LEARNING STUDIES ON PUBMED.COM****TOTAL NUMBER OF STUDIES****b****STUDIES PER SPECIALTY**

Source: https://www.reddit.com/r/appliedatahoarding/comments/14ok07m/number_of_medical_ai_studies_by_year_from_2010_to/

Accessed 2/1/24



Health AI Market Size 2014 - 2021



Acquisitions of AI startups are rapidly increasing while the health market is set to register an explosive CAGR of 40% through 2021.

Source: Accenture (December 2017). Artificial Intelligence in Healthcare.

GLOBAL ARTIFICIAL INTELLIGENCE IN HEALTHCARE MARKET

ARTIFICIAL INTELLIGENCE (AI) IN HEALTHCARE Market

OPPORTUNITIES AND FORECAST, 2021-2030

Artificial Intelligence (AI) in Healthcare Market is expected to reach **194.14 Billion** by 2030.

Growing at a **CAGR of 38.1%** (2021-2030)

Growing at a **CAGR of 48.7%** (2017-2023)

GLOBAL ARTIFICIAL INTELLIGENCE IN HEALTHCARE MARKET BY GEOGRAPHY



Asia-Pacific region would exhibit the highest **CAGR of 53.4%** during 2017-2023.

[Source: Artificial Intelligence in Healthcare Market | Global Report – 2030 \(alliedmarketresearch.com\)](https://www.alliedmarketresearch.com/artificial-intelligence-in-healthcare-market)



OCTOBER 30, 2023

FACT SHEET: President Biden Issues Executive Order on Safe, Secure, and Trustworthy Artificial Intelligence

[BRIEFING ROOM](#)[STATEMENTS AND RELEASES](#)

Today, President Biden is issuing a landmark Executive Order to ensure that America leads the way in seizing the promise and managing the risks of artificial intelligence (AI). The Executive Order establishes new standards for AI safety and security, protects Americans' privacy, advances equity and civil rights, stands up for consumers and workers, promotes innovation and competition, advances American leadership around the world, and more.

As part of the Biden-Harris Administration's comprehensive strategy for responsible innovation, the Executive Order builds on previous actions the President has taken, including work that led to voluntary commitments from 15 leading companies to drive safe, secure, and trustworthy development of AI.

<https://www.whitehouse.gov/briefing-room/statements-releases/2023/10/30/fact-sheet-president-biden-issues-executive-order-on-safe-secure-and-trustworthy-artificial-intelligence/>

Shanghai 1990



Shanghai 2020



Subscribe Latest Issues

SCIENTIFIC AMERICAN. Sign In | Newsletters

COVID Health Mind & Brain Environment Technology Space & Physics Video Podcasts Opinion



Save 40% on Unlimited [Subscribe](#)

SPACE & PHYSICS

China Reaches New Milestone in Space-Based Quantum Communications

The nation's Micius satellite successfully established an ultrasecure link between two ground stations separated by more than 1,000 kilometers

By Karen Kwon on June 25, 2020 [أعرض هذا باللغة العربية](#)



What is China's GDP as per PPP?

Economy of China

Statistics

GDP	\$19.373 trillion (nominal; 2023 est.) \$33.014 trillion (PPP; 2023 est.)
GDP rank	2nd (nominal; 2023) 1st (PPP; 2023)
GDP growth	8.4% (2021) 3.0% (2022) 5.2% (2023f) 4.5% (2024f)

Central Intelligence Agency (.gov)
<https://www.cia.gov> > field > country-comparison

Real GDP (purchasing power parity)

Rank	Country	Real GDP (PPP)	Date of Information
1	China	\$24,861,000,000,000	2021 est.
2	United States	\$21,132,000,000,000	2021 est.
3	India	\$9,279,000,000,000	2021 est.

Patient-Facing

AI Chatbots



Wearables & Devices



Personalized Genetics



Mental Health



Women's Health



Skin



Telehealth

Telemedicine



Lifestyle Management



Disease Management



AI in Healthcare

Research


Drug Discovery



Information & Clinical Trials



Genetic Research



Doctor-Facing

Medical Records



Data Analytics



Medical Imaging



Hospital



IS THIS A GUTENBERG MOMENT?



IS THIS A GUTENBERG MOMENT?

Envisioning the Healthcare Landscape with ChatGPT

New York Medical College Explores The Opportunities And Risks Of AI On The Healthcare Industry In The Following Article Written Entirely Using ChatGPT

February 13, 2023

Opinion > Kevin, M.D.

AI in Healthcare: Meeting HIPAA Standards With ChatGPT

— Patients deserve a commitment to privacy

by Harvey Castro, MD, MBA February 11, 2023

ChatGPT Passes US Medical Licensing Exam Without Clinician Input

ChatGPT achieved 60 percent accuracy on the US Medical Licensing Exam, indicating its potential in advancing artificial intelligence-assisted medical education.



THE LANCET
Digital Health

COMMENT | [ONLINE FIRST](#)

ChatGPT: the future of discharge summaries?

Sajan B Patel • Kyle Lam [✉](#)

[Open Access](#) • Published: February 06, 2023 • DOI: [https://doi.org/10.1016/S2589-7500\(23\)00021-3](https://doi.org/10.1016/S2589-7500(23)00021-3)

New and surprising evidence that ChatGPT can perform several intricate tasks relevant to handling complex medical and clinical information

[Download PDF Copy](#)



By [Neha Mathur](#)

Reviewed by [Danielle Ellis, B.Sc.](#)

Feb 13 2023

FORBES > INNOVATION > HEALTHCARE


EDITORS' PICK

5 Ways ChatGPT Will Change Healthcare Forever, For Better

[Robert Pearl, M.D.](#) Contributor [Ⓞ](#)


[Follow](#)

IMPORTANCE OF AI IN ONCOLOGY



AI IN RADIATION ONCOLOGY


Automatic delineation of tumors and organs at risk



Comparison of sketch speed of target area:

AI takes 10-20 minutes
Manual work takes 4-5 hours


AI DETECTING PROSTATE CANCER NEAR PERFECTION



- Images from more than 1M parts of stained tissue slides from patient biopsies used to teach AI to discriminate between healthy and abnormal tissue
- Tested on 1,600 slides from 100 patients
- AI demonstrated 98% sensitivity and 97% specificity at detecting prostate cancer
- AI also flagged 6 slides not noted by expert pathologists

[An artificial intelligence algorithm for prostate cancer diagnosis in whole slide images of core needle biopsies: a blinded clinical validation and deployment study - The Lancet Digital Health](#)

EFFICIENCIES FOR SYSTEMS AND PROVIDERS



LeanTaaS

Unlocking Healthcare Capacity and Access with Technology and Lean Transformation

A photograph of a man in a suit sitting at a desk, working on a laptop. A futuristic, glowing blue and white interface is overlaid on the laptop screen and extends into the foreground.

How Novant Health Optimized OR Capacity to Restore Elective Surgery & Achieve Stronger Financial Health

INTEGRATION SOLUTION

Eon is a powerful supplement to Epic.

The Eon logo is in the top right corner. Below it is a large, white, multi-layered spiral graphic that creates a sense of depth and movement against the black background.

CAPACITY MANAGEMENT

LeanTaaS Overview

Silicon Valley, Charlotte and Boston based software company

- PhDs in Mathematics, Software Engineers, Product Managers, Operations Experts, Hospital Executives

\$350+ Million invested in predictive analytics platform “iQueue”

Mission: Unlock capacity of scarce assets using predictive and prescriptive analytics:

- Improve patient access
- Increase volumes and revenues
- Reduce wait time for patients
- Reduce operating costs
- Defer the need for facility expansion

6 Patents Pending

Awards & 3rd Party Validation



Gartner



605

Leading Hospitals

14 of top 20

Health Systems

175

Health Systems

46

States in the U.S.



CAPACITY MANAGEMENT



- AI powered patient flow optimization, like RTLS, ensures patients move through a facility, with the right level of care, as efficiently as possible.
- AI optimized schedule management gives clinicians more time with their patients
- AI decision support algorithms improve the ability of front-line doctors and caregivers to make more accurate diagnoses and provide better treatment.
- Immediate gains in reducing clinical errors

INNOVATION THAT BENEFITS PROVIDERS AND PATIENTS

MEDTECH

FDA clears Paige's AI as first program to spot prostate cancer in tissue slides

By **Conor Hale** • Sep 22, 2021 11:59am

JAMA | **Original Investigation** | INNOVATIONS IN HEALTH CARE DELIVERY

Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs

EDITORIAL

Deep Learning Algorithms for Detection of Lymph Node Metastases From Breast Cancer Helping Artificial Intelligence Be Seen

Jeffrey Alan Golden, MD

AI Partnership to Advance Brain Tumor Research, Treatment

Hackensack Meridian Health and Neosoma, Inc. have announced a collaboration aimed at tackling difficult-to-treat brain tumors through the use of artificial intelligence.

Radiology:Artificial Intelligence

Improving Breast Cancer Detection Accuracy of Mammography with the Concurrent Use of an Artificial Intelligence Tool

Serena Pacilè, PhD • January Lopez, MD • Pauline Chone, MPhil • Thomas Bertinotti, MSc • Jean Marie Grosin, PhD • Pierre Fillard, PhD

NEJM
Evidence

Published March 28, 2022

NEJM Evid 2022; 1 (5)

DOI: [10.1056/EVIDoa2100058](https://doi.org/10.1056/EVIDoa2100058)

ORIGINAL ARTICLE

AI Estimation of Gestational Age from Blind Ultrasound Sweeps in Low-Resource Settings

Teeranan Pokaprakarn, Ph.D.,¹ Juan C. Prieto, Ph.D.,² Joan T. Price, M.D., M.P.H.,^{3,4} Margaret P. Kasaro, M.D., M.P.H.,^{3,5} Ntazana Sindano, B.Sc.,³ Hina R. Shah, M.S.,² Marc Peterson, M.S.,⁴ Mutinta M. Akapelwa, B.Sc.,³ Filson M. Kapilya, B.Sc.,³ Yuri V. Sebastião, Ph.D.,⁴ William Goodnight III, M.D., M.S.,⁴ Elizabeth M. Stringer, M.D., M.Sc.,⁴ Bethany L. Freeman, M.P.H., M.S.W.,⁴ Lina M. Montoya, Ph.D.,¹ Benjamin H. Chi, M.D., M.Sc.,^{3,4} Dwight J. Rouse, M.D., M.S.P.H.,⁶ Stephen R. Cole, Ph.D.,⁷ Bellington Vwalika, M.D., M.Sc.,^{4,5} Michael R. Kosorok, Ph.D.,¹ and Jeffrey S. A. Stringer, M.D.^{3,4}

JAMA Guide to Statistics and Methods

Using Free-Response Receiver Operating Characteristic Curves to Assess the Accuracy of Machine Diagnosis of Cancer

Chaya S. Medowetz, PhD

JAMA | **Original Investigation**

Diagnostic Assessment of Deep Learning Algorithms for Detection of Lymph Node Metastases in Women With Breast Cancer

Babak Ehteshami Bejnordi, MS; Mitko Veta, PhD; Paul Johannes van Diest, MD, PhD; Bram van Ginneken, PhD; Nico Karssemeijer, PhD; Geert Litjens, PhD; Jeroen A. W. M. van der Laak, PhD; and the CAMELYON16 Consortium

HEALTH TECH

White House unveils CancerX innovation accelerator, new funding for cancer screenings on Moonshot anniversary

INNOVATION THAT BENEFITS PROVIDERS AND PATIENTS

ChatGPT has 'great potential' to improve cancer prevention and screening, study finds



How Chatbots and Large Language Model Artificial Intelligence Systems Will Reshape Modern Medicine: Fountain of Creativity or Pandora's Box?

Li R¹, Kumar A¹, Chen JH¹

[Author information](#) ▶

JAMA Internal Medicine, 28 Apr 2023,

DOI: [10.1001/jamainternmed.2023.1835](https://doi.org/10.1001/jamainternmed.2023.1835) PMID: 37115531

JAMA Internal Medicine | [Original Investigation](#)

Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media Forum

John W. Ayers, PhD, MA; Adam Pollak, PhD; Mark Dredze, PhD; Eric C. Leas, PhD, MPH; Zechariah Zhu, BS; Jessica B. Kelley, MSN; Dennis J. Faix, MD; Aaron M. Goodman, MD; Christopher A. Longhurst, MD, MS; Michael Hogarth, MD; Davey M. Smith, MD, MAS

Medicine in the Era of Artificial Intelligence: Hey Chatbot, Write Me an H&P.

Brender TD¹

[Author information](#) ▶

JAMA Internal Medicine, 28 Apr 2023,

DOI: [10.1001/jamainternmed.2023.1832](https://doi.org/10.1001/jamainternmed.2023.1832) PMID: 37115537

April 28, 2023

Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media Forum



John W. Ayers, PhD, MA^{1,2}; Adam Poliak, PhD³; Mark Dredze, PhD⁴; [et al](#)

Results Of the 195 questions and responses, evaluators preferred chatbot responses to physician responses in 78.6% (95% CI, 75.0%-81.8%) of the 585 evaluations. Mean (IQR) physician responses were significantly shorter than chatbot responses (52 [17-62] words vs 211 [168-245] words; $t=25.4$; $P<.001$). Chatbot responses were rated of significantly higher quality than physician responses ($t=13.3$; $P<.001$). The proportion of responses rated as *good* or *very good* quality (≥ 4), for instance, was higher for chatbot than physicians (chatbot: 78.5%, 95% CI, 72.3%-84.1%; physicians: 22.1%, 95% CI, 16.4%-28.2%). This amounted to 3.6 times higher prevalence of *good* or *very good* quality responses for the chatbot. Chatbot responses were also rated significantly more empathetic than physician responses ($t=18.9$; $P<.001$). The proportion of responses rated *empathetic* or *very empathetic* (≥ 4) was higher for chatbot than for physicians (physicians: 4.6%, 95% CI, 2.1%-7.7%; chatbot: 45.1%, 95% CI, 38.5%-51.8%; physicians: 4.6%, 95% CI, 2.1%-7.7%). This amounted to 9.8 times higher prevalence of *empathetic* or *very empathetic* responses for the chatbot.

Conclusions In this cross-sectional study, a chatbot generated quality and empathetic responses to patient questions posed in an online forum. Further exploration of this technology is warranted in clinical settings, such as using chatbot to draft responses that physicians could then edit. Randomized trials could assess further if using AI assistants might improve responses, lower clinician burnout, and improve patient outcomes.

WORLD'S FIRST REAL-TIME CONVERSATIONAL AI ONCOLOGY MENTOR FOR CANCER PATIENTS

Dave - Belong AI Oncology Mentor



Dave AI Oncology Mentor

Hello. It's not uncommon to be concerned about the potential risks associated with cancer treatments. While it's true that radiation therapy can occasionally increase the risk of developing certain types of cancer later in life, this risk is generally quite small. Read more

This is an Artificial Intelligence (AI) generated answer. Always consult with professionals before making decisions



"*Dave* provides smart, personalized and accessible information instantaneously, which can greatly improve the quality of care and life for millions of patients worldwide," said Eiran Malki, Co-founder and CEO of Belong.Life. "Belong is currently developing additional conversational AI mentor and companion platforms for other health indications and organizations."

CURRENT LIMITATIONS AND CHALLENGES

Healthcare Algorithms Are Biased, and the Results Can Be Deadly

Deep-learning algorithms suffer from a fundamental problem: They can adopt unwanted biases from the data on which they're trained. In healthcare, this can lead to bad diagnoses and care recommendations.

How Bias Can Creep into Health Care Algorithms and Data


Health care is rife with bias. Without careful attention, AI will perpetuate those inequities.

Amazon Still Pushing Biased Facial-Recognition Software To Law Enforcement, MIT Researcher Contends

Biases in Artificial Intelligence Led to Healthcare Disparities
Researchers from the US and China note that several biases found in artificial intelligence design perpetuate healthcare disparities.

Racial bias in a medical algorithm favors white patients over sicker black patients

A US government study confirms most face recognition systems are racist



TANGIBLE BENEFITS AND ROI



Improves
Data
Analysis



Better
Diagnosis and
Treatment
Predictions



Frees Medical
Staff from
Administrative
Burdens

Contrary to fears that machines will replace human workers, AI in healthcare may help “re-humanize” healthcare

CHANGING THE HEALTHCARE LANDSCAPE

Streamlining Workflows

Reducing Costs

Improving Collaboration

Advancing Research

Empowering Patients

AI STANDARDS AND ADOPTION

FUTURE TRENDS AND INNOVATIONS

Equity

Evidence

Sustainability

Policy


Education

“People Analytics” and Large Scale Databanks: Blurring the Boundaries Between Medical Research, Clinical Care and Daily Life

- every monitored event (clinical and non-clinical) is a potential data point
- every individual is a data node
- every individual is a research asset
- every individual is their own control

ISSN: 2993-091X

AI^{IN} PRECISION ONCOLOGY



Mary Ann Liebert, Inc. publishers

www.liebertpub.com/alpo

Mary Ann Liebert, Inc. publishers

www.liebertpub.com/alpo

“In essence, *AI in Precision Oncology* is more than a scientific or medical journal; it is a mission-driven initiative to harness the power of AI in improving oncology care. We aim to shape an AI-enabled health care system that is equitable, efficient, and patient centered – making health care more human.”

– Dr. Douglas Flora

 SOPHIA GENETICS™

**AI-Driven
Precision Oncology
Summit**

NASDAQ World Headquarters
New York, Sept. 26TH 2023



The State of AI in Precision Oncology

REGISTRATION NOW OPEN!

The State of AI in Precision Oncology

A virtual summit hosted by *AI in Precision Oncology*, the groundbreaking new peer-reviewed journal from Mary Ann Liebert, Inc.

DISTINGUISHED SPEAKERS INCLUDE



SCAN TO REGISTER NOW

Learn more at liebertpub.com/aipo

The State of AI in Precision Oncology
 December 12, 2023 | 11:00–4:00 ET
REGISTER NOW
 HOSTED BY AI IN PRECISION ONCOLOGY
 SPONSORED BY EXACT SCIENCES

The State of AI in Precision Oncology
 December 12, 2023 | 11:00–4:00 ET
 HOSTED BY AI IN PRECISION ONCOLOGY
 SPONSORED BY EXACT SCIENCES
REGISTER NOW

The State of AI in Precision Oncology
 December 12, 2023 | 11:00–4:00 ET
 HOSTED BY AI IN PRECISION ONCOLOGY
 SPONSORED BY EXACT SCIENCES
Announcing The State of AI in Precision Oncology
 A virtual summit hosted by *AI in Precision Oncology*, the groundbreaking new peer-reviewed journal from Mary Ann Liebert, Inc.
 December 12, 2023
 11:00–4:00 ET
Register for Free Now
 The impact of artificial intelligence in medicine is being felt most strongly in the field of oncology, offering clinicians a host of previously unimaginable opportunities to personalize treatments and save lives. The inaugural *State of AI in Precision Oncology* brings together world-renowned physicians, oncologists, and AI experts to discuss the current and future prospects of AI in precision oncology, including the applications of AI in early cancer detection, treatment planning, drug discovery, data management, and much more.
Speakers Include:
 Eric Topol, MD
 Scripps Research
 Blythe Adamson, PhD
 Flatiron Health
 Scott Penberthy, PhD
 Google
 Nikhil G. Thaker, MD
 Capital Health
 Sarah McGough, PhD
 Genentech
 Arturo Loiza-Bonilla, MD
 Massive Bio
Register for Free Now
 The State of AI in Precision Oncology will also feature a live panel discussion with the opportunity to ask your most pressing questions about the field. [Submit your questions now](#) to ensure they're answered live on December 12th.
 The State of AI in Precision Oncology is sponsored by
EXACT SCIENCES
 Mary Ann Liebert, Inc. publishers



SCAN TO REGISTER NOW

Learn more at liebertpub.com/aipo

ACCC 2022-2023 PRESIDENT'S THEME

*Leveraging Technology to Transform Cancer
Care Delivery and the Patient Experience*

David R. Penberthy, MD, MBA


Associate Professor of Radiation Oncology
Penn State Health Milton S. Hershey Medical Center
Hershey, Pennsylvania



ASSOCIATION OF COMMUNITY CANCER CENTERS (ACCC)

ACCC 2022-23 President's Theme Tech Talk #1
The Home as a New Site of Cancer Care

Thursday, July 14, 2022



ASSOCIATION OF COMMUNITY CANCER CENTERS (ACCC)

ACCC 2022-2023 President's Theme Tech Talk #2
Technology Solutions to Mitigate the
Workforce Shortage


Thursday, August 18, 2022



ASSOCIATION OF COMMUNITY CANCER CENTERS (ACCC)

ACCC 2022-2023 President's Theme Tech Talk #3
Applying a Health Equity Lens to
Implementing Remote Patient Monitoring


Thursday, November 10, 2022



ASSOCIATION OF COMMUNITY CANCER CENTERS (ACCC)

ACCC 2022-2023 President's Theme Tech Talk #4
The Impact of Big Data and Artificial
Intelligence on Oncology

Wednesday, February 15, 2023



TO LEARN MORE ABOUT THE 2022-2023 ACCC PRESIDENT'S THEME



Scan the QR Code or Visit
[ACCC-CANCER.ORG/PRESIDENTS-THEME](https://acc-cancer.org/presidents-theme)

Introducing Digital Human

Digital Human:

- Is lifelike animated avatar
- Can be customized exterior and interior
- Can recognize real-time situations
- Can react them like human



Type of Digital Human

	Interactive	Not Interactive
Non-Existing Character	Auto Reception/ Auto Kiosk/ Digital Assistant	Virtual Model/ Influencer
Existing Character	Digital Clone of Specialist	Video Guide for Museum

Spotlight on: Disease & Patient Insights

Cultivating **tumor-agnostic** insights in light of the evolving paradigm of anti-cancer treatment

12



PRECISION ONCOLOGY NEWS

Business & Policy Biomarkers Cancer Specialties Oncology Trends Resources

[Home](#) » [Disease Areas](#) » [Cancer](#)


Industry Interest in Pan-Cancer Indications Growing With FDA Support Despite Challenges

May 29, 2019 | [Turna Ray](#)

FDA NEWS RELEASE

FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor


13




BIOPHARMA DIVE Deep Dive Library Events Topics

Roche cancer drug the 3rd approved for pan-tumor use

Published Aug. 15, 2019 • Updated Aug. 15 2019, 3:15 p.m. PDT

 **Ned Pagliarulo**
Lead Editor

[in](#) [f](#) [t](#) [e](#) [p](#)




14

Spotlight on: Clinical Trial Design

How can we create broader and more inclusive clinical trials without compromising estimates of treatment effects?

Clinical Trials



Real World



The Horizon: What's Next for Big Data & Machine Learning in Industry?

- **Scaling** insights
- **Operationalizing** tools—embedding data-driven analytics in clinical practice
- Weighing **ethics** and **risk to patient** **interpretation, fair models**


Forbes AI 50 2023
\$27B funding!



The future is bright!



Phenome (WGS + LPR) cohorts can *stratify* diseases, from first principles.



Source: Schork, Nicholas. [Personalized Medicine: Time for one-person trials.](#) Nature. Vol 520, April 2015.

The Phenomics Revolution is coming.



The Phenomics Revolution

Science is poised to shift the focus of health care to well care—the prediction and prevention of disease rather than just treating the sick

BY DAVID EWING DUNCAN

In 2017, I got a call from Ginger Hultin, my brand-new health data coach. She was concerned, she said, about my TMAOs.

"My what?" I asked.

"Your TMAOs," she repeated, referring to trimethylamine-N-oxide, a metabolite that's excreted by bacteria in the stomach that at high-er-than-average levels can increase a person's risk for heart disease.

Who knew?

Not to worry, said Hultin in a soothing, upbeat voice. I could reduce my score by cutting back on red meat, which TMAO-secreting bacteria love to gorge on.

Trimethylamine-N-oxides were part of a battery of tests I had taken a few weeks earlier when Hultin's employer, a Seattle start-up called Arivale that had collected copious amounts of my blood, saliva, and stool to test hundreds of biomarkers. These included DNA markers, proteins, metabolites, lipids like cholesterol, and the microbiome in my gut.

The company had also sent me a Fitbit to measure steps, sleep, and heart rate. Online they had asked endless questions about my health, medical history, happiness, stress, and more to add to my digital health report card; information that was integrated with my other data using advanced computers and algorithms to produce the report that Hultin and I were discussing. The goal was for me, a basically hale and hearty man in my fifties, to find out just how healthy I really was—both then and in the future.

Still on the phone, Hultin asked me to scroll to a section called "Genes" in my online Arivale profile. "Do you see the finding about vitamin D?" she asked. "Yep" I said, checking my result for a gene called VDR. It indicated that I had a mutation that makes it difficult for my body to absorb vitamin D. "This is probably why your vitamin D level is low," she said, referring to yet another section of my profile. Not dangerously so, though she suggested that I start taking a vitamin supplement.

I was impressed. I had spent years as a reporter trying out hundreds of newfangled tests like these to see what they might reveal about the health of an actual human, findings that I had chronicled in my

2009 book *Experimental Man* and in dozens of articles before and after, including a 2017 story in *NEO LIFE*, "The Radical Idea of Avoiding Sickness." Most of them, however, had been too new, experimental, and incomplete to tell me much.

Arivale's data and analysis was different. It seemed more scientifically sound; and, more important, it seemed believable.

Yes, the company was testing just a small number of bio-data points, a few hundred out of the thousands that might be influencing, say, my risk for heart disease. Nor was TMAO likely to have an immediate influence—or much influence at all compared to other risk factors—on whether my heart would keep happily beating, or would one day seize up. Yet the report was telling me things that few people hear about who take standard exams. I also was being given choices based on my own specific data about how to intervene in my own healthcare—for instance, to rein in the burgers and BBQ pulled pork sandwiches or face the consequences.

I remember feeling like I had just gotten a check-up from the future...

At the time, I remember feeling like I had just gotten a check-up from the future, something that scientists and entrepreneurs had repeatedly promised me during my experimental man project, but seldom delivered on. This wasn't surprising

given the complexity of human biology and the newness of the science, although I had been wondering when all of this would finally come together to

SCIENTIFIC AMERICAN®

Digital Tools in Cancer Care

RPM Technologies Survey Findings

FULL REPORT



Advisory Committee



Amanda Dean Martin, DNP, CENP, ACNP-BC

Chief of Clinical Integration
Banner MD Anderson Cancer Center
Phoenix, AZ



David Penberthy, MD, MBA

Associate Professor of Radiation
Oncology, Penn State Health,
Milton S. Hershey Medical Center
Hershey, PA



Ramy Sedhom, MD

Clinical Assistant Professor; Faculty, Penn
Center for Cancer Care Innovation
Penn Medicine, Princeton Health
Princeton, NJ



Jeff Hunnicutt

Chief Executive Officer
Highlands Oncology Group
Fayetteville, AK



Erin Pierce MSN, APRN, FNP-C

Nurse Practitioner; Manager of
Ochsner Precision Cancer
Therapies Program
Ochsner Cancer Institute
New Orleans, LA



Cardinale Smith, MD, PhD

Director of Quality for Cancer Services
Mount Sinai Health System
New York, NY



Jeffrey Kendall, Psy.D., LP

Director, Oncology Supportive Care
M Health Fairview
Minneapolis, MN



**Anne Marie F. Rainey, MSN RN
CHC**

Director of Quality and Value-
Based Care
Clearview Cancer Institute
Huntsville, AL



Sydney Townsend, MPAff, PMP

Director, Virtual Care
Texas Oncology
Austin, TX



Adam Dicker, MD, PhD, FASTRO, FASCO

Senior Vice President, Enterprise
Radiation Oncology
Jefferson Health
Philadelphia, PA

Methodology

Patients and Caregivers:

Online survey (n=162)



- 90 cancer patients
 - currently undergoing treatment or treated in last 3 years



- 72 caregivers
 - caregivers to patients with cancer currently undergoing treatment or treated in last 3 years

Fielded January 4 – 23, 2023



Providers:

Online survey (n=128)

- Distributed by ACCC
- n=58 from SERMO
- N=70 from ACCC

Fielded December 21, 2022 – January 23, 2023

Methodological Limitations:

Potential sampling bias among patients & caregivers

- 1% of sample had concerns around access to a smartphone or computer as a potential barrier

Subgroups for Analysis

Patients	Caregivers	Urban	Suburban	Rural	Patient age <65	Patient age 65+	Person of Color	Not POC
n=90	n=72*	n=45	n=83	n=34	n=65	n=97	n=63*	n=98

*Caregivers and persons of color skewed younger.

Providers	Community	Academic/N CI	Private	Admin	Physicians	Nurses	Urban	Suburban	Rural	Implemented/Implementing RPM	Considering/Planning/Pilot RPM	Not considering RPM
n=128	n=51	n=49	n=26*	n=23*	n=67	n=23*	n=74	n=38	n=16*	n=36	n=51	n=36

▲ ▼ Denotes statistically significantly higher/lower than adjacent comparison group @90% CL

▲ ▼ Denotes statistically significantly higher/lower than adjacent comparison group @95% CL

*sample sizes below n=30 are considered extremely small and should be viewed with caution

Key Findings: Patients and Caregivers

1

Open to using digital tools to report symptoms

- Most patients and caregivers are **open to using technology to report symptoms** during cancer treatment
- More than half report either using technology already or considering its use
- **Caregivers are more likely to already use technology** to report symptoms and share symptoms that normally wouldn't come up during an appointment.

2

See the value in reporting symptoms

- Patients, caregivers, and providers agree that **keeping the healthcare team up to date and alerting if medical treatment is necessary** are the top reasons to use technology
- Providers also see improving outcomes and reducing hospitalizations as top benefits – a potential opportunity area to educate patients on additional benefits

3

Need in-person tech support and privacy/cost concerns addressed

- **Patients and caregivers feel that meeting in-person to help set-up technology is the most helpful**, particularly among rural and older respondents
- Patients and caregivers are **most concerned about the privacy of health data and cost of using technology**
- **Clear gap** between what patients want for technology support and what providers are offering

Key Findings: Cancer Programs

1

Concerns around confidence and accuracy

- While providers see benefits to RPM, they also **express only weak confidence in their own use of digital technology as well as cautious about the accuracy of data provided** by patients and caregivers
- Perceptions of benefits are lower among practices not considering RPM suggesting there is outreach and education to do

2

Admin as RPM advocates & disconnect between training and use

- **Admins appear to be greatest advocates for RPM** – encouraging adoption and expressing concern about patient accessibility
- Does not appear that training is happening consistently
- **While nurses are identified as key roles for monitoring RPM data, they report the least experience with it**

3

Great momentum and resulting need for RPM implementation support

- **Most cancer programs (7 in 10) reported at least early planning for RPM, with 3 in 10 programs having already implemented the technology**
- Many are already using EHR patient portals and/or text messaging to communicate
- **Implementation support needed** includes strategies for funding/reimbursement, business case examples, training, and success stories.


Use of Technology

Across Patient, Caregiver, and Provider audiences, there are groups of respondents who have embraced technology and others who are not planning to adopt it.


Use Technology to Track Health Information During Cancer Treatment




Patients



Caregivers



Providers





Technology
changes.....

What Can A Quantum Computer Do Better?

Quantum computing will solve a class of problems that are unsolvable today, opening up a new realm of applications.



03

SEARCHING BIG DATA




DESIGNING BETTER DRUGS & NEW MATERIALS



MACHINE LEARNING



How CRISPR works



illumina

illumina wants to sequence your whole genome for \$100

\$100

Posted Jan 10, 2017 by Sarah Buhr (@sarahbuhr)



Next Story

Popular Posts



Buttrcup is a risqué image site that pays creators




Snap CEO Evan Spiegel got a \$637 million bonus last year



Blockchain is entering the valley of despair phase, and that's a m...



SpaceX misses catching Falcon 9 rocket falling with a giant net on a big ship



The first sequencing of the whole human genome in 2003 cost roughly \$2.7 billion, but DNA sequencing giant **illumina** has now unveiled a new machine that the company says is "expected one day" to order up your whole genome for less than \$100.

EARN 80,000 BONUS POINTS FOR YOUR BUSINESS.

LEARN MORE

CHASE ^Q BUSINESS SO YOU CAN

AdChoices

Crunchbase

illumina

FOUNDED 1998

OVERVIEW
At illumina, their goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies



In 2012, scientists at the University of Leicester decided to print out a complete version of the human genome. When they were done, they had a 130-volume monument to humanity's essence—a seemingly endless sequence of As, Ts, Cs, and Gs in four-point type. Curiously, the printing project's costs already exceeded the costs of actually sequencing the genome anew. Since then, the price differential has only grown. Cas Kramer (Univ. Leicester) »



PUBLIC

PRIVATE





ChatGPT: What Did You Just Say?


- Generative Artificial Intelligence
 - Text-based and visual **artificial intelligence** tools
 - Goal of solving problems, accomplishing tasks with human-like responses and answers
 - These algorithms can answer almost any question generate text, audio, music, video, images, art, code, music, make arguments, form ideas, and much more
 - GPT stands for **Generative Pre-Trained Transformer**—this is a natural language processing model

[Midjourney.com](https://www.midjourney.com)

[Openai.com/dall-e-2](https://openai.com/dall-e-2)

[Faceapp.com](https://www.faceapp.com)

CHRONIC HEALTH CONDITIONS EXPECTED TO BENEFIT MOST FROM AI/ML



Data curation and retrieval, not retention

FUTURE FORCE IN ONCOLOGY

- 1 Prevention and treatment advances will redefine the cancer “consumer”**
- 2 Rapid innovation will remake the requirements of contemporary care**
- 3 Unsustainable costs will prompt intervention across the value chain**
- 4 Traditional provider identities will blur, creating new ecosystems of care**
- 5 New entrants will accelerate disruption and innovation in the care continuum**

WHAT CANCER CENTERS NEED TO DO

Excel in the spaces before and after cancer, addressing the needs of millions of cancer “pre-vivors” and survivors.

Build care models that reflect the complexity of the disease, capable of adapting to high-velocity clinical innovation.

Diversify the business model and create value-based competence, preparing for challenges to today’s onco-economics.

Redefine target patient segments and the role of partnerships in a marketplace of fungible community and academic roles.

Assemble the expertise and capabilities required to modernize the experience of cancer care.

THE PROMISE OF AI & ML IN HEALTHCARE



21st century curricular emphasis

- **Knowledge capture and curation:** Teaching students to distinguish between information and knowledge. Stresses knowledge capture and curation not information retention.
- **Deep understanding of probabilistic reasoning:** understanding probabilities and communicating and applying them meaningfully
- **Collaboration with and management of AI applications**
- **Cultivation of empathy and compassion**

“If you’re teaching today what you were five years ago;
either the field is dead or you are.”



-- Noam Chomsky

Easter Parades in New York City

Year 1900: One Motor Vehicle

Year 1913: One Horse & Carriage







Change is accelerating
Stay alert & engaged
Be open to possibilities
...and buckle up!





Q & A



Additional suggested reading



Navy
times



References

1. Jakubowski DM, Bailey H, Abran A, et al. Molecular characterization of breast cancer needle core biopsy specimens by the 21-gene Breast Recurrence Score test. *J Surg Oncol*. 2020;122(4):611-618. doi: 10.1002/jso.26050
2. Li MM, Datto M, Duncavage EJ, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. *J Mol Diagn*. 2017;19(1):4-23. doi: 10.1016/j.jmoldx.2016.10.002
3. Li K, Lou H, Huang L, et al. Microsatellite instability: a review of what the oncologist should know. *Cancer Cell Int*. 2020;20:16. doi: 10.1186/s12935-019-1091-8
4. Brauns J, Pauwels P. Tumor mutational burden: a review. *Belg J Med Oncol*. 2020;14(1):4-7. <https://www.bjmo.be/journal-article/tumour-mutational-burden-a-review/>
5. Albain KS, Zlobin AY, Covington KR, et al. Identification of a notch-driven breast cancer stem cell gene signature for anti-notch therapy in an ER+ presurgical window model. 2014 San Antonio Breast Cancer Symposium. 2014; San Antonio, Texas.
6. Colomer R, Mondejar R, Romero-Laorden N, et al. When should we order a next generation sequencing test in a patient with cancer? *EClinicalMedicine*. 2020;25:100487. doi: 10.1016/j.eclinm.2020.100487
7. IQVIA. Supporting precision oncology: targeted therapies, immuno-oncology, and predictive biomarker-based medicines. Published August 11, 2020. <https://www.iqvia.com/insights/the-iqvia-institute/reports/supporting-precision-oncology>
8. Torres GF, Bonilla CE, Buitrago G, et al. How clinically useful is comprehensive genomic profiling for patients with non-small cell lung cancer? A systematic review. *Crit Rev Oncol Hematol*. 2021;166:103459. doi: 10.1016/j.critrevonc.2021.103459
9. Chakravarty D, Johnson A, Sklar J, et al. Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion. *J Clin Oncol*. 2022;40(11):1231-1258. doi: 10.1200/JCO.21.02767
10. Sarhadi VK, Armengol G. Molecular biomarkers in cancer. *Biomolecules*. 2022;12(8):1021. <https://doi.org/10.3390/biom12081021>
11. Pritchard D, Goodman C, Nadauld LD. Clinical utility of genomic testing in cancer care. *JCO Precis Oncol*. 2022;6:e2100349. doi: 10.1200/PO.21.00349
12. Ray T. Industry interest in pan-cancer indications growing with FDA support despite challenges. Published May 29, 2019. Accessed February 13, 2023. <https://www.precisiononcologynews.com/cancer/industry-interest-pan-cancer-indications-growing-fda-support-despite-challenges#Y-p523bMJD8>
13. Pagliarulo N. Roche cancer drug the 3rd approved for pan-tumor use. Published August 15, 2019. Accessed February 13, 2023. <https://www.biopharmadive.com/news/roche-rozlytrek-cancer-drug-approval-tumor-agnostic/561027/#:~:text=Rozlytrek%2C%20as%20the%20drug%20will,another%20mutation%20known%20as%20ROS1.>
14. U.S. Food & Drug Administration. FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor. Published August 15, 2019. Accessed February 13, 2023. <https://www.fda.gov/news-events/press-announcements/fda-approves-third-oncology-drug-targets-key-genetic-driver-cancer-rather-specific-type-tumor>
15. Liu R, Rizzo S, Whipple S, Pal N, et al. Evaluating eligibility criteria of oncology trials using real-world data and AI. *Nature*. 2021;592:629-633. <https://www.nature.com/articles/s41586-021-03430-5>
16. Benedum C, Adamson B, Cohen AB, et al. P57 machine learning-accelerated outcomes research: A real-world case study of biomarker-associated overall survival in oncology. *Value Health*. 2022;25(12):S13-S14. <https://doi.org/10.1016/j.jval.2022.09.069>

REFERENCES

1. American Cancer Society. Cancer facts & figures: 2019. Published 2019. Accessed August 15, 2022. <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf>
2. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. *CA Cancer J Clin.* 2019;69(5):363-385. doi: 10.3322/caac.21565
3. Weir HK, Thompson TD, Stewart SL, et al. Cancer incidence projections in the United States between 2015 and 2050. *Prev Chronic Dis.* 2021;18:210006. doi: <http://dx.doi.org/10.5888/pcd18.210006>
4. American Cancer Society. Cancer facts & figures: 2022. Accessed August 15, 2022. <https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html>
5. Yang W, Williams JH, Hogan PF, et al. Projected supply of and demand for oncologists and radiation oncologists through 2025: an aging, better-insured population will result in shortage. *J Oncol Pract.* 2014;10(1):39-45. doi: 10.1200/JOP.2013.001319
6. Google. Tacoma, Washington. Accessed August 16, 2022. <https://www.google.com/maps/place/Tacoma,+WA/@47.3945599,-123.1267825,8.29z/data=!4m5!3m4!1s0x549054ee2b659567:0x62219c07ebb09e82!8m2!3d47.2528768!4d-122.4442906>
7. Hale C. FDA clears Paige's AI as first program to spot prostate cancer in tissue slides. Published September 22, 2021. Accessed August 17, 2022. <https://www.fiercebiotech.com/medtech/fda-clears-paige-s-ai-as-first-program-to-spot-prostate-cancer-amid-tissue-slides#:~:text=MedTech,FDA%20clears%20Paige's%20AI%20as%20first%20program,prostate%20cancer%20in%20tissue%20slides&text=Tech%20companies%20have%20been%20questing,clearance%20to%20do%20just%20that>
8. Moskowitz CS. Using free-response receiver operating characteristic curves to assess the accuracy of machine diagnosis of cancer. *JAMA.* 2017;318(22):2250-2251. doi: 10.1001/jama.2017.18686
9. Gulshan V, Peng L, Coram M, et al. Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. *JAMA.* 2016;316(22):2402-2410. doi:10.1001/jama.2016.17216
10. Pokaprakarn T, Prieto JC, Price JT, et al. AI estimation of gestational age from blind ultrasound in low-resource settings. *NEJM Evid.* 2022. doi: <https://doi.org/10.1056/EVIDoA2100058>
11. Golden JA. Deep learning algorithms for detection of lymph node metastases from breast cancer: helping artificial intelligence be seen. *JAMA.* 2017;318(22):2184-2186. doi: 10.1001/jama.2017.14580
12. Pacile S, Lopez J, Chone P, et al. Improving breast cancer detection accuracy of mammography with the concurrent use of an artificial intelligent tool. *Radiol Artif Intell.* 2020;2(6):e190208. doi: 10.1148/ryai.2020190208
13. Ehteshami Bejnordi B, Veta M, Johannes van Diest P, et al. Diagnostic assessment of deep learning algorithms for detection of lymph node metastases in women with breast cancer. *JAMA.* 2017;318(22):2199-2210. doi:10.1001/jama.2017.14585
14. Ibx Medical Analytics. Prostate biopsy with cancer probability (blue is low, red is high). Published July 27, 2020. Accessed August 17, 2022. <https://www.eurekalert.org/news-releases/558575>
15. Indigo BioAutomation. Process, review, and release GC/LC-MS data. Accessed August 17, 2022. <https://info.indigobio.com/ascent-demo>
16. LeanTaaS, Becker's Hospital Review. How Novant Health optimized OR capacity to restore elective surgery & achieve stronger financial health. Accessed August 17, 2022. https://iqueue.leantaas.com/Beckers-Feb-23-2021-Community-Hospitals-Virtual-Forum_Registration.html
17. LeanTaaS. Unlocking healthcare capacity and access with technology and lean transformation. Accessed August 17, 2022. <https://iqueue.leantaas.com/OR-manager-unlocking-healthcare-capacity-eBook-download.html>
18. Epic. Homepage. Accessed August 17, 2022. <https://www.epic.com/>
19. Copan. PhenoMatrix®. Accessed August 17, 2022. <https://www.copanusa.com/full-lab-automation-and-artificial-intelligence/phenomatrix/>
20. Eon. Eon Blogs: Eon + Epic. Published February 11, 2021. Accessed August 17, 2022. <https://eonhealth.com/blog/eon-epic/#:~:text=Eon%20is%20a%20powerful%20supplement%20to%20Epic.&text=The%20Eon%20solution%20incorporates%20high,and%20achieve%20documented%20patient%20outcomes>
21. Access Intelligence, LLC. ORManager. Accessed August 17, 2022. <https://www.ormanager.com/>
22. Michele Doying, The Verge. A doctor explains how artificial intelligence could improve the patient-doctor bond. Published March 12, 2019. Accessed August 12, 2022. <https://www.theverge.com/2019/3/12/18261718/eric-topol-deep-medicine-artificial-intelligence-algorithms-health-science-interview>



Thank you!

TO THE BEACH

A hand-drawn sign on a white rectangular background, hanging from a tree branch. The sign features the text "TO THE BEACH" in a playful, hand-painted font. The words "TO" and "BEACH" are in black, while "THE" is in blue. To the right of the text are hand-drawn illustrations: a yellow sun with black rays, blue wavy lines representing water, and several small black birds in flight. The sign is suspended by white string from a tree branch, with green foliage in the background.



“Don’t believe everything you read on the Internet just because there’s a picture with a quote next to it.”

—Abraham Lincoln